
In a study using the MUP-uPA mouse model of metabolic dysfunction-associated steatohepatitis (MASH), bi-weekly treatment with HEXA-FC, a long-lasting HEXA analog, improved hepatic steatosis, hepatocyte ballooning, and glycemic control in mild MASH and insulin resistance. The treatment enhanced hepatic fatty acid oxidation and peripheral glucose disposal without affecting endogenous glucose production. However, HEXA-FC was ineffective against severe MASH and liver fibrosis, suggesting its potential for treating mild MASH and type 2 diabetes.
Like
Save
Share